1. Scrip
  2. >>Business

INTERVIEW: Robert Wessman On Growing Generics, And Why Biosimilars Will Dominate The Future

 
• By John Davis

Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.

SC1606_Wessman-and-friends_1200
Alvotech's New Facilities Opening Ceremony: Robert Wessman (center), Eef Schimmelpennink (right) and Fjalar Kristjansson (left). • Source: Alvotech.

Having been CEO of Actavis in the 2000s, when he transformed that company from an Iceland-based contract manufacturer into a generics sector leader, Robert Wessman is showing that process was no fluke or accident - his current company Alvogen Inc., that he joined in 2009, is approaching annual sales of nearly a billion dollars a year, and annual earnings of around $300m.

But when asked what to look out for from generics companies in the future, Wessman said the trend will likely...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.